Literature DB >> 10634674

Noninvasive evaluation of cardiac dysfunction by echocardiography in streptozotocin-induced diabetic rats.

B D Hoit1, C Castro, G Bultron, S Knight, M A Matlib.   

Abstract

BACKGROUND: There has not been a noninvasive in vivo longitudinal evaluation of cardiac function in diabetic rats. The objective of this study is to examine the time course of development of cardiac dysfunction in streptozotocin (STZ)-induced diabetic rats. METHODS AND
RESULTS: Cardiac function was evaluated by M-mode and Doppler echocardiography in anesthetized Wistar rats at 2, 4, 5, 6, and 8 weeks after injection with 65 mg of STZ/kg and in age-matched control rats before and after the administration of isoproterenol. Body weight (BW) was significantly less and blood glucose level significantly greater in diabetic rats compared with controls at 2 weeks and remained at these levels at all time points. The calculated left ventricular (LV) mass appeared slightly decreased in diabetic rats. However, LV mass-BW ratios were similar in controls and diabetic rats at 2, 4, and 5 weeks, but were significantly greater in diabetic rats at 6 and 8 weeks. Basal heart rate (HR) was significantly lower in diabetic rats at all time points studied. Basal LV systolic and diastolic dimensions, fractional shortening (FS), velocity of circumferential shortening (Vcf), peak emptying rate (PER), peak filling rate (PFR), and aortic peak velocity (APV) were not significantly different between controls and diabetic rats at 2 and 4 weeks. PER and PFR were significantly less in 5-week diabetic rats. However, Vcf, PER, and PFR were significantly less and FS and APV were similar at 6 and 8 weeks. Administration of isoproterenol increased HR, Vcf, FS, PFR, and PER in controls at all time points, but the increases in diabetic rats at 5, 6, and 8 weeks were less compared with those in controls. The increase in APV was significantly less in diabetic rats at all time points studied.
CONCLUSION: STZ-induced diabetic rats showed bradycardia before contractile dysfunction. Overt and covert contractile dysfunction unmasked by isoproterenol begins at 5 weeks of diabetes. The overt LV systolic and diastolic dysfunction are fully manifested after 6 weeks of diabetes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10634674     DOI: 10.1016/s1071-9164(99)91337-4

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  28 in total

1.  Effects of the association of diabetes and pulmonary emphysema on cardiac structure and function in rats.

Authors:  Antonio Di Petta; Rafael Simas; Clebson L Ferreira; Vera L Capelozzi; Vera M C Salemi; Luiz F P Moreira; Paulina Sannomiya
Journal:  Int J Exp Pathol       Date:  2015-10-29       Impact factor: 1.925

2.  cAMP-dependent Protein Kinase (PKA) Signaling Is Impaired in the Diabetic Heart.

Authors:  Lee B Bockus; Kenneth M Humphries
Journal:  J Biol Chem       Date:  2015-10-14       Impact factor: 5.157

3.  Propagation of the cardiac impulse in the diabetic rat heart: reduced conduction reserve.

Authors:  A Nygren; M L Olson; K Y Chen; T Emmett; G Kargacin; Y Shimoni
Journal:  J Physiol       Date:  2006-12-21       Impact factor: 5.182

Review 4.  Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment.

Authors:  Inês Falcão-Pires; Adelino F Leite-Moreira
Journal:  Heart Fail Rev       Date:  2012-05       Impact factor: 4.214

5.  Estrogen-Dependent Disruption of Adiponectin-Connexin43 Signaling Underlies Exacerbated Myocardial Dysfunction in Diabetic Female Rats.

Authors:  Korin E Leffler; Abdel A Abdel-Rahman
Journal:  J Pharmacol Exp Ther       Date:  2018-12-06       Impact factor: 4.030

6.  Estrogen-dependent hypersensitivity to diabetes-evoked cardiac autonomic dysregulation: Role of hypothalamic neuroinflammation.

Authors:  Mohamed A Fouda; Korin E Leffler; Abdel A Abdel-Rahman
Journal:  Life Sci       Date:  2020-03-31       Impact factor: 5.037

7.  Cardiac-specific IGF-1 receptor transgenic expression protects against cardiac fibrosis and diastolic dysfunction in a mouse model of diabetic cardiomyopathy.

Authors:  Karina Huynh; Julie R McMullen; Tracey L Julius; Joon Win Tan; Jane E Love; Nelly Cemerlang; Helen Kiriazis; Xiao-Jun Du; Rebecca H Ritchie
Journal:  Diabetes       Date:  2010-03-09       Impact factor: 9.461

Review 8.  Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations.

Authors:  Cecilia C Low Wang; Connie N Hess; William R Hiatt; Allison B Goldfine
Journal:  Circulation       Date:  2016-06-14       Impact factor: 29.690

9.  Effects of MCC-135 on Ca2+ uptake by sarcoplasmic reticulum and myofilament sensitivity to Ca2+ in isolated ventricular muscles of rats with diabetic cardiomyopathy.

Authors:  Naoya Satoh; Yoshimi Kitada
Journal:  Mol Cell Biochem       Date:  2003-07       Impact factor: 3.396

10.  Role of differential signaling pathways and oxidative stress in diabetic cardiomyopathy.

Authors:  Kenichi Watanabe; Rajarajan A Thandavarayan; Meilei Harima; Flori R Sari; Narasimman Gurusamy; Punniyakoti T Veeraveedu; Sayaka Mito; Wawaimuli Arozal; Vijayakumar Sukumaran; Arun Prasath Laksmanan; Vivian Soetikno; Makoto Kodama; Yoshifusa Aizawa
Journal:  Curr Cardiol Rev       Date:  2010-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.